Potential Geographic "hotspots" for Drug-injection Related Transmission of HIV and HCV and for Initiation into Injecting Drug Use in New York City, 2011-2015, with Implications for the Current Opioid Epidemic in the US

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2018 Mar 30

PMID 29596464

Citations 13

Authors

D C Des Jarlais

H L F Cooper

K Arasteh

J Feelemyer

C McKnight

Z Ross

Affiliations

Soon will be listed here.

Abstract

Objective: We identified potential geographic "hotspots" for drug-injecting transmission of HIV and hepatitis C virus (HCV) among persons who inject drugs (PWID) in New York City. The HIV epidemic among PWID is currently in an "end of the epidemic" stage, while HCV is in a continuing, high prevalence (> 50%) stage.

Methods: We recruited 910 PWID entering Mount Sinai Beth Israel substance use treatment programs from 2011-2015. Structured interviews and HIV/ HCV testing were conducted. Residential ZIP codes were used as geographic units of analysis. Potential "hotspots" for HIV and HCV transmission were defined as 1) having relatively large numbers of PWID 2) having 2 or more HIV (or HCV) seropositive PWID reporting transmission risk-passing on used syringes to others, and 3) having 2 or more HIV (or HCV) seronegative PWID reporting acquisition risk-injecting with previously used needles/syringes. Hotspots for injecting drug use initiation were defined as ZIP codes with 5 or more persons who began injecting within the previous 6 years.

Results: Among PWID, 96% injected heroin, 81% male, 34% White, 15% African-American, 47% Latinx, mean age 40 (SD = 10), 7% HIV seropositive, 62% HCV seropositive. Participants resided in 234 ZIP codes. No ZIP codes were identified as potential hotspots due to small numbers of HIV seropositive PWID reporting transmission risk. Four ZIP codes were identified as potential hotspots for HCV transmission. 12 ZIP codes identified as hotspots for injecting drug use initiation.

Discussion: For HIV, the lack of potential hotspots is further validation of widespread effectiveness of efforts to reduce injecting-related HIV transmission. Injecting-related HIV transmission is likely to be a rare, random event. HCV prevention efforts should include focus on potential hotspots for transmission and on hotspots for initiation into injecting drug use. We consider application of methods for the current opioid epidemic in the US.

Citing Articles

Insights into the spatial epidemiology of hepatitis C infection: systematic synthesis of area-level determinants and spatiotemporal analyses.

Gizamba J, Finch B, Wang S, Klausner J BMC Public Health. 2025; 25(1):687.

PMID: 39972312 PMC: 11841175. DOI: 10.1186/s12889-025-21668-w.

Impact of Local and Demographic Factors on Early COVID-19 Vaccine Hesitancy among Health Care Workers in New York City Public Hospitals.

Afzal A, Shariff M, Perez-Gutierrez V, Khalid A, Pili C, Pillai A Vaccines (Basel). 2022; 10(2).

PMID: 35214729 PMC: 8879070. DOI: 10.3390/vaccines10020273.

The Association Between Homophily on Illicit Drug Use and PrEP Conversations Among Latino Men Who Have Sex with Men Friends: A Dyadic Network and Spatially Explicit Study.

Kanamori M, Shrader C, Johnson A, Arroyo-Flores J, Rodriguez E, Skvoretz J Arch Sex Behav. 2021; 51(5):2485-2495.

PMID: 34791583 PMC: 10102898. DOI: 10.1007/s10508-021-02131-4.

Chronic hepatitis-C infection in COVID-19 patients is associated with in-hospital mortality.

Ronderos D, Omar A, Abbas H, Makker J, Baiomi A, Sun H World J Clin Cases. 2021; 9(29):8749-8762.

PMID: 34734053 PMC: 8546815. DOI: 10.12998/wjcc.v9.i29.8749.

Role of direct and indirect social and spatial ties in the diffusion of HIV and HCV among people who inject drugs: a cross-sectional community-based network analysis in New Delhi, India.

Clipman S, Mehta S, Srikrishnan A, Zook K, Duggal P, Mohapatra S Elife. 2021; 10.

PMID: 34342266 PMC: 8370773. DOI: 10.7554/eLife.69174.

References

Des Jarlais D, Perlis T, Settembrino J . The use of electronic debit cards in longitudinal data collection with geographically mobile drug users. Drug Alcohol Depend. 2004; 77(1):1-5. DOI: 10.1016/j.drugalcdep.2004.06.010. View

Sorensen J, Copeland A . Drug abuse treatment as an HIV prevention strategy: a review. Drug Alcohol Depend. 2000; 59(1):17-31. DOI: 10.1016/s0376-8716(99)00104-0. View

Rudd R, Aleshire N, Zibbell J, Gladden R . Increases in Drug and Opioid Overdose Deaths--United States, 2000-2014. MMWR Morb Mortal Wkly Rep. 2016; 64(50-51):1378-82. DOI: 10.15585/mmwr.mm6450a3. View

Kuo M, Janjua N, Burchell A, Buxton J, Krajden M, Gilbert M . Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011. Am J Public Health. 2015; 105(8):1604-10. PMC: 4504305. DOI: 10.2105/AJPH.2015.302591. View

Des Jarlais D, Arasteh K, McKnight C, Feelemyer J, Hagan H, Cooper H . Combined HIV prevention, the New York City condom distribution program, and the evolution of safer sex behavior among persons who inject drugs in New York City. AIDS Behav. 2013; 18(3):443-51. PMC: 3947424. DOI: 10.1007/s10461-013-0664-0. View

Des Jarlais D, Perlis T, Friedman S, Deren S, Chapman T, Sotheran J . Declining seroprevalence in a very large HIV epidemic: injecting drug users in New York City, 1991 to 1996. Am J Public Health. 1998; 88(12):1801-6. PMC: 1509056. DOI: 10.2105/ajph.88.12.1801. View

Bluthenthal R, Kral A, Gee L, Erringer E, Edlin B . The effect of syringe exchange use on high-risk injection drug users: a cohort study. AIDS. 2000; 14(5):605-11. DOI: 10.1097/00002030-200003310-00015. View

Eckhardt B, Winkelstein E, Shu M, Carden M, McKnight C, Des Jarlais D . Risk factors for hepatitis C seropositivity among young people who inject drugs in New York City: Implications for prevention. PLoS One. 2017; 12(5):e0177341. PMC: 5438142. DOI: 10.1371/journal.pone.0177341. View

Des Jarlais D, Diaz T, Perlis T, Vlahov D, Maslow C, Latka M . Variability in the incidence of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus infection among young injecting drug users in New York City. Am J Epidemiol. 2003; 157(5):467-71. DOI: 10.1093/aje/kwf222. View

10.

Des Jarlais C, Perlis T, Friedman S, Chapman T, Kwok J, Rockwell R . Behavioral risk reduction in a declining HIV epidemic: injection drug users in New York City, 1990-1997. Am J Public Health. 2000; 90(7):1112-6. PMC: 1446283. DOI: 10.2105/ajph.90.7.1112. View

11.

Des Jarlais D, Arasteh K, McKnight C, Feelemyer J, Tross S, Perlman D . Racial/Ethnic Disparities at the End of an HIV Epidemic: Persons Who Inject Drugs in New York City, 2011-2015. Am J Public Health. 2017; 107(7):1157-1163. PMC: 5463217. DOI: 10.2105/AJPH.2017.303787. View

12.

Boodram B, Golub E, Ouellet L . Socio-behavioral and geographic correlates of prevalent hepatitis C virus infection among young injection drug users in metropolitan Baltimore and Chicago. Drug Alcohol Depend. 2010; 111(1-2):136-45. DOI: 10.1016/j.drugalcdep.2010.04.003. View

13.

Murrill C, Prevots D, Miller M, Linley L, Royalty J, Gwinn M . Incidence of HIV among injection drug users entering drug treatment programs in four US cities. J Urban Health. 2001; 78(1):152-61. PMC: 3456197. DOI: 10.1093/jurban/78.1.152. View

14.

Tempalski B, Pouget E, Cleland C, Brady J, Cooper H, Hall H . Trends in the population prevalence of people who inject drugs in US metropolitan areas 1992-2007. PLoS One. 2013; 8(6):e64789. PMC: 3673953. DOI: 10.1371/journal.pone.0064789. View

15.

Dowdy D, Golub J, Chaisson R, Saraceni V . Heterogeneity in tuberculosis transmission and the role of geographic hotspots in propagating epidemics. Proc Natl Acad Sci U S A. 2012; 109(24):9557-62. PMC: 3386125. DOI: 10.1073/pnas.1203517109. View

16.

Diaz T, Des Jarlais D, Vlahov D, Perlis T, Edwards V, Friedman S . Factors associated with prevalent hepatitis C: differences among young adult injection drug users in lower and upper Manhattan, New York City. Am J Public Health. 2001; 91(1):23-30. PMC: 1446499. DOI: 10.2105/ajph.91.1.23. View

17.

Rockwell R, Des Jarlais D, Friedman S, Perlis T, Paone D . Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care. 1999; 11(4):437-42. DOI: 10.1080/09540129947811. View

18.

Paull S, Song S, McClure K, Sackett L, Kilpatrick A, Johnson P . From superspreaders to disease hotspots: linking transmission across hosts and space. Front Ecol Environ. 2013; 10(2):75-82. PMC: 3589764. DOI: 10.1890/110111. View

19.

Des Jarlais D, Arasteh K, McKnight C, Perlman D, Feelemyer J, Hagan H . HSV-2 co-infection as a driver of HIV transmission among heterosexual non-injecting drug users in New York City. PLoS One. 2014; 9(1):e87993. PMC: 3909306. DOI: 10.1371/journal.pone.0087993. View

20.

Wand H, Ramjee G . Targeting the hotspots: investigating spatial and demographic variations in HIV infection in small communities in South Africa. J Int AIDS Soc. 2010; 13:41. PMC: 2984578. DOI: 10.1186/1758-2652-13-41. View